Abstract
Purpose :
Photodynamic therapy (PDT) combined with intravitreal anti-vascular endothelial growth factor (VEGF) agents is currently a first-line treatment for polypoidal choroidal vasculopathy (PCV). In this study, we investigate association between long-term treatment outcome and anatomic characteristics using enhanced depth imaging optical coherence tomography (EDI-OCT) and indocyanine green (ICG) angiography in eyes with PCV.
Methods :
In this retrospective, observational study, medical charts of fifteen eyes of 15 patients (6 men) with treatment-naive PCV undergoing PDT combined with intravitreal ranibizumab followed by pro re nata (PRN) ranibizumab were reviewed. EDI-OCT and ICG angiography were performed at baseline and last visit. Greatest linear dimension (GLD) defined with ICG angiography were measured. The luminal choroidal areas were also measured using binarization of the images obtained by EDI-OCT. Pachychoroid neovasculopathy (PNV) was diagnosed based on the previous report (Miyake et al. Sci Rep 2015;5:16204). The relationship between the timing of recurrence and the 4 explanatory variables (GLD, the total or luminal choroidal areas at baseline, and PNV or not) were calculated using a linear model.
Results :
The mean age was 73.7 ± 5.8 years. The mean follow-up period was 5.8 ± 2.2 years. The average timing of recurrence was 2.8±2.2 years (range, 0.3-7.4). The mean best-corrected visual acuity (BCVA) improved from 0.30±0.22 at baseline to 0.14±0.27 at the final visit (P=0.03). The diagnosis as PNV was the only factor significantly associating with longer timing of recurrence (P<.0001).
Conclusions :
In the present study, the long-term visual outcome was favorable after intravitreal ranibizumab combined with PDT for PCV, but the timing of recurrence was variable. The diagnosis of PNV might be associated with the timing of recurrence.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.